Allurion Technologies, Inc. (ALUR)

Allurion Technologies' stock price has been impacted by several significant events in the past six months. The company received a delisting notice from the NYSE for failing to meet continued listing standards, which impacted investor confidence. The FDA approved the PMA application for the Allurion Gastric Balloon System, which Allurion cited as a crucial step in its plan to regain NYSE compliance or relist. Allurion announced the exercise of outstanding warrants, which generated approximately $3.0 million in gross proceeds. Allurion announced preliminary, unaudited results for Q4 and full-year 2025, expecting Q4 revenue of $3.3M–$3.7M and full-year revenue of approximately $15M. Allurion Technologies continued to report substantial operating losses and faced ongoing concerns regarding its significant debt burden and cash burn. Allurion Technologies reported a notable decline in its Q3 2025 revenue, falling to $2.7 million from $5.4 million in the same period last year.

Based on historical data, Allurion Technologies, Inc. Common Stock (ALUR) shows distinct seasonal tendencies. Historically, October has been the strongest month for ALUR, with an average return of 0.62% and a win rate of 60%. Conversely, August tends to be the weakest month, averaging a -21.90% return. The overall monthly win rate for the full calendar year is 40.6%, with only one month typically showing positive average returns. The seasonal pattern has a consistency score of 34.2 (Poor), indicating it has not been highly reliable across different market conditions. The company itself has acknowledged observing seasonality due to summer months, which impacted its Q3 2025 revenue.

Allurion Technologies, Inc. (ALUR) is a medical device company focused on addressing obesity through its comprehensive weight-loss platform, the Allurion Program. The company operates in the healthcare sector, specifically in the medical devices and instruments industry, and is also categorized under Specialized Consumer Services and Consumer Services. Allurion's primary product is the Allurion Program, which features the Allurion Gastric Balloon System, including the Allurion Smart Capsule, the world's first and only swallowable, procedure-less gastric balloon for weight loss. The Allurion Program also integrates the Allurion Virtual Care Suite, which includes the Allurion Mobile App for consumers, Allurion Insights for healthcare providers, and the Allurion Connected Scale and Health Tracker devices. Allurion is also exploring combination approaches with GLP-1 medications, focusing on adherence and long-term outcomes.

Allurion Technologies is headquartered in Natick, Massachusetts, United States, with a corporate office in Paris, France. The Allurion Balloon holds the CE Mark in Europe and is available in over 50 countries across the Middle East, Latin America, and Asia. The U.S. Food and Drug Administration (FDA) approved the premarket approval (PMA) application for the Allurion Gastric Balloon System, featuring the Allurion Smart Capsule. Key international markets include Spain, Italy, and France, where sales resumed in February 2025 after a regulatory suspension.

Allurion Technologies positions itself as a pioneer in metabolically healthy weight loss, emphasizing its non-surgical approach and comprehensive program. The company highlights its commitment to upholding high-quality standards, as evidenced by passing Bioresearch Monitoring (BIMO) inspections with no observations and completing a Day-100 meeting with the FDA without requests for additional human clinical data. The recent FDA approval of the Allurion Gastric Balloon System in February 2026 is a significant positive for its reputation. However, the company's reputation has faced challenges, including the NYSE delisting notice in March 2026, a significant revenue decline in Q3 2025, and persistent operating losses and heavy cash burn.

Allurion Technologies Inc. (ALUR) has 28 institutional owners and shareholders holding a total of 6,823,487 shares. Major institutional owners include RTW Investments, LP, Lunt Capital Management, Inc., and Toronto Dominion Bank. Individual insiders who own company stock include Shantanu Gaur (CEO and Co-Founder) and Michael R. Davin (Member of the Board of Directors). As of March 2026, 8.10% of the stock is held by insiders, and 21.39% by institutions. Hedge funds hold 48% of the company's shares. Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 105.9%.